Change in Orion Group Executive Management Board as of 1 January 2012

Mr. Pekka Konsi, Senior Vice President responsible for the Supply Chain line function of the Orion Group and member of the Executive Management Board of the Orion Group will retire in the beginning of 2012 and will step aside from his current position as of 1 January 2012.   

Mrs. Virve Laitinen, M.Sc. (Tech.), MBA, currently Director of Orion's Business Planning and Control function, has been appointed Senior Vice President responsible for the Supply Chain line function and member of the Executive Management Board of the Orion Group, as of 1 January 2012.

Timo Lappalainen, President and CEO, says:

"Pekka Konsi has led the development of Orion's Supply Chain operations to meet the changing needs of pharmaceutical supply. It is my pleasure to thank Pekka for his long lasting and distinguished career at Orion. Pekka's successor, Virve has extensive experience of Orion's operations and supply chain. I welcome Virve to become a member of Orion's Executive Management Board."   

The CV of Virve Laitinen is attached and a photo of her is available also on the homepage of Orion, at http://materialbank.orion.fi / Public Content Bank / Management photographs / Other people.

Orion Corporation

Contact person:
Timo Lappalainen, President and CEO, phone +358 50 966 3692

Appendix: The CV of Virve Laitinen

APPENDIX

The CV of  Virve Laitinen

Virve Laitinen

M.Sc. (Technology), Industrial Management, University of Technology, Helsinki, 1998

MBA, Henley Management College, UK, 2007

Born 1972

Senior Vice President, Supply Chain, since 1 January 2012

Career

Virve Laitinen joined Orion 1997. She has since occupied the following positions:

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo
www.orion.fi

Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler® pulmonary drugs.

The Group's net sales in 2010 amounted to EUR 850 million. The Company invested EUR 85 million in research and development. At the end of 2010, the Group had a total of approximately 3,100 employees, of whom 2,450 worked in Finland and 650 in other countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.